17. Trade and other receivables and other current assets
|
31 December |
|
(thousands of €) |
2020 |
2019 |
Non-current trade receivables |
50,000 |
- |
Trade receivables |
134,632 |
39,603 |
Prepayments |
219 |
292 |
Other receivables |
13,568 |
14,114 |
Trade and other receivables |
148,418 |
54,009 |
Inventories |
355 |
255 |
Accrued income |
1,096 |
4,443 |
Deferred charges |
10,502 |
4,439 |
Other current assets |
11,953 |
9,138 |
Total trade and other receivables & other current assets |
210,371 |
63,147 |
Non-current and current trade and other receivables increased primarily due to the outstanding receivable as at 31 December 2020 of €160.0 million on Gilead related to the recently renegotiated agreement of December 2020 for filgotinib. We refer to note 2 Summary of significant transaction for more details.
We consider that the carrying amount of trade and other receivables approximates their fair value.
The other current assets mainly included accrued income from subsidy projects and deferred charges.
On 31 December 2020, we did not have any provision for expected credit losses.